Cargando…

History of Research on Tumor Angiogenesis

In 1971, J. Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that t...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Ribatti, Domenico (Autor)
Autor Corporativo: SpringerLink (Online service)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Dordrecht : Springer Netherlands : Imprint: Springer, 2009.
Edición:1st ed. 2009.
Temas:
Acceso en línea:Texto Completo

MARC

LEADER 00000nam a22000005i 4500
001 978-1-4020-9563-4
003 DE-He213
005 20220126132547.0
007 cr nn 008mamaa
008 100301s2009 ne | s |||| 0|eng d
020 |a 9781402095634  |9 978-1-4020-9563-4 
024 7 |a 10.1007/978-1-4020-9563-4  |2 doi 
050 4 |a RC261-271 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
072 7 |a MJCL  |2 thema 
082 0 4 |a 571.978  |2 23 
082 0 4 |a 616.994  |2 23 
100 1 |a Ribatti, Domenico.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
245 1 0 |a History of Research on Tumor Angiogenesis  |h [electronic resource] /  |c by Domenico Ribatti. 
250 |a 1st ed. 2009. 
264 1 |a Dordrecht :  |b Springer Netherlands :  |b Imprint: Springer,  |c 2009. 
300 |a X, 126 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
520 |a In 1971, J. Folkman published in the "New England Journal of Medicine" a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis. Beginning in the 1980's, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy. This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors. 
650 0 |a Cancer. 
650 0 |a Oncology. 
650 0 |a Science-History. 
650 0 |a Pathology. 
650 0 |a Cytology. 
650 1 4 |a Cancer Biology. 
650 2 4 |a Oncology. 
650 2 4 |a History of Science. 
650 2 4 |a Pathology. 
650 2 4 |a Cell Biology. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9789048181568 
776 0 8 |i Printed edition:  |z 9781402095641 
776 0 8 |i Printed edition:  |z 9781402095597 
856 4 0 |u https://doi.uam.elogim.com/10.1007/978-1-4020-9563-4  |z Texto Completo 
912 |a ZDB-2-SBL 
912 |a ZDB-2-SXB 
950 |a Biomedical and Life Sciences (SpringerNature-11642) 
950 |a Biomedical and Life Sciences (R0) (SpringerNature-43708)